Monitoring altered plasmatic levels of PROS1 or incorporating its assessment during therapy could aid in identifying COVID-19 subjects at higher risk for PROS1-associated coagulopathies, which can significantly exacerbate the clinical course in COVID-19 patients. This evidence concerns the gene PROS1 and COVID-19.